JA Medical Cordis_Redacted.pdf

Controlled Unclassified Information (CUI)

Page | 2

Source Selection Information - FAR 2.101 and 3.104

5. The use of this authority is necessary because the current cardiovascular and endovascular marketplace consists of manufacturers that produce their "Unique" or "Highly specialized" own line of products. Unlike many other industries, product selection in the cardiovascular and endovascular industry are not based solely on price and is overshadowed by physician experience and highly specialized training on use of specific surgical items. A physician’s training with a particular manufacturer’s product increases their aptitude and familiarity with the technical characteristics of the products that are expected to produce a higher quality of life for their patients or achieve certain therapeutic results. Cordis US Corp. cardiovascular and endovascular products are unique and proprietary, as is the industry standard, and require highly specialized training on the part of the physician. The manufacturers’ product will consistently be used due to a physician’s experience, training, and preference.

In addition, the Cordis US Corp. representatives are experts on the vendor’s products and are a vital part of helping to ensure that the patient is getting the necessary treatment. At the request of Medical Treatment Facilities (MTFs), Cordis US Corp. will have a qualified representative on site at the MTF within the timeframe specified by the facility necessary to meet their requirements. The representative provides technical advice and guidance to the physician before, during, and after implantation. Having a representative with technical knowledge of the products provides better patient care during and after a procedure.

Furthermore, technical support is available twenty-four (24) hours a day, seven (7) days a week as the facility and surgeon will have access to the representative’s direct phone number.

There are no known manufacturers or distributors other than Cordis US Corp. that can provide requiring medical facilities with the complete surgical devices and instruments (catheters, sheaths, guidewires, PTCA balloons, stents, etc.) under all three delivery methods and have the ability to provide support with regard to Cordis products and surgical procedures. As technology advances or further product lines are required by the MTFs, additional products determined to be sole source to Cordis US Corp. may be added to the contract. All product lines added to the contract must be within the scope of the solicitation. Separate technical certification(s) supporting an amendment to this Justification for Other Than Full and Open Competition will be prepared and approved prior to addition to the contract. All items proposed for addition to the contract will be synopsized and the prices will be determined fair and reasonable prior to placement on the contract.

6. A Sources Sought Notice (SSN) was issued to ensure that offers are solicited from as many sources as is practicable. The SSN was issued on November 29, 2021, via the Beta.SAM.gov website seeking sources capable of providing Cordis US Corp. cardiovascular and endovascular products and closed on December 29, 2021. Cordis US Corp. was the only company that expressed interest in the proposed acquisition.

As required by FAR 5.2, the acquisition was synopsized on January 18, 2022, in Contract Opportunities (Beta.SAM.GOV). In addition, this justification will be published with the solicitation in accordance with FAR 6.305(c).

Page | 5

Source Selection Information - FAR 2.101 and 3.104

I have reviewed and hereby approve this justification.

Date WILLIAM J. KENNY Executive Director, Troop Support Contracting and Acquisition Management

KENNY.WILLIA

M.J.122896882

Digitally signed by

KENNY.WILLIAM.J.1228968

Date: 2022.04.01 10:33:37 -04'00'